메뉴 건너뛰기




Volumn 3, Issue 1, 2005, Pages 81-89

Therapies for HIV and viral hepatitis coinfection

Author keywords

Alcohol; Hepatitis B virus; Hepatitis C virus; Highly active antiretroviral therapy; HIV; Pegylated interferon; Substance abuse

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ENTECAVIR; ERYTHROPOIETIN; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; LIVER ENZYME; NEVIRAPINE; NUCLEOSIDE ANALOG; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

EID: 14044276938     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.1.81     Document Type: Review
Times cited : (2)

References (99)
  • 1
    • 0003185326 scopus 로고    scopus 로고
    • HIV/AIDS Surveillance Report. US HIV and AIDS cases reported through December 2002
    • HIV/AIDS Surveillance Report. US HIV and AIDS cases reported through December 2002. Centers for Disease Control and Prevention. 14, 1-48 (2002).
    • (2002) Centers for Disease Control and Prevention , vol.14 , pp. 1-48
  • 2
    • 0033584440 scopus 로고    scopus 로고
    • The prevalence of hepatitis C virus infection in the USA, 1988 through 1994
    • Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the USA, 1988 through 1994. N. Engl. J. Med. 341(8), 556-562 (1999).
    • (1999) N. Engl. J. Med. , vol.341 , Issue.8 , pp. 556-562
    • Alter, M.J.1    Kruszon-Moran, D.2    Nainan, O.V.3
  • 3
    • 0036828784 scopus 로고    scopus 로고
    • The burden of hepatitis C in the United States
    • Kim WR. The burden of hepatitis C in the United States. Hepatology 36(5 Suppl. 1), S30-S34 (2002).
    • (2002) Hepatology , vol.36 , Issue.5 SUPPL. 1
    • Kim, W.R.1
  • 4
    • 0032916690 scopus 로고    scopus 로고
    • Update on diagnosis, management and prevention of hepatitis B virus infection
    • Mahoney FJ. Update on diagnosis, management and prevention of hepatitis B virus infection. Clin. Microbiol. Rev. 12(2), 351-366 (1999).
    • (1999) Clin. Microbiol. Rev. , vol.12 , Issue.2 , pp. 351-366
    • Mahoney, F.J.1
  • 5
    • 0007815709 scopus 로고    scopus 로고
    • Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: Prevalence and prognostic value
    • 12th World AIDS Conference. Geneva, Switzerland, 28 June-3 July (Abstract 22261)
    • Stubble L, Soriano V, Antunes F. Hepatitis C in the EuroSIDA Cohort of European HIV-infected patients: prevalence and prognostic value. 12th World AIDS Conference. Geneva, Switzerland, 28 June-3 July 1998 (Abstract 22261).
    • (1998)
    • Stubble, L.1    Soriano, V.2    Antunes, F.3
  • 6
    • 0030978971 scopus 로고    scopus 로고
    • Needle exchange is not enough: Lessons from the Vancouver injecting drug use study
    • Strathdee SA, Patrick DM, Currie SL et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 11(8), F59-F65 (1997).
    • (1997) AIDS , vol.11 , Issue.8
    • Strathdee, S.A.1    Patrick, D.M.2    Currie, S.L.3
  • 7
    • 0037181727 scopus 로고    scopus 로고
    • Protection against persistence of hepatitis C
    • Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 359(9316), 1478-1483 (2002).
    • (2002) Lancet , vol.359 , Issue.9316 , pp. 1478-1483
    • Mehta, S.H.1    Cox, A.2    Hoover, D.R.3
  • 8
    • 0026028252 scopus 로고
    • Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection
    • Hadler SC, Judson FN, O'Malley PM et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J. Infect. Dis. 163(3), 454-459 (1991).
    • (1991) J. Infect. Dis. , vol.163 , Issue.3 , pp. 454-459
    • Hadler, S.C.1    Judson, F.N.2    O'Malley, P.M.3
  • 9
    • 8044229048 scopus 로고    scopus 로고
    • Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection
    • Gilson RJ, Hawkins AE, Beecham MR et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 11(5), 597-606 (1997).
    • (1997) AIDS , vol.11 , Issue.5 , pp. 597-606
    • Gilson, R.J.1    Hawkins, A.E.2    Beecham, M.R.3
  • 10
    • 0028129404 scopus 로고
    • Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study
    • Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 84(4), 1020-1023 (1994).
    • (1994) Blood , vol.84 , Issue.4 , pp. 1020-1023
    • Eyster, M.E.1    Fried, M.W.2    Di Bisceglie, A.M.3    Goedert, J.J.4
  • 11
    • 0032995925 scopus 로고    scopus 로고
    • HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy
    • Dragoni F, Cafolla A, Gentile G et al. HIV-HCV RNA loads and liver failure in coinfected patients with coagulopathy. Haematologica 84(6), 525-529 (1999).
    • (1999) Haematologica , vol.84 , Issue.6 , pp. 525-529
    • Dragoni, F.1    Cafolla, A.2    Gentile, G.3
  • 12
    • 0032503230 scopus 로고    scopus 로고
    • Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters
    • Beld M, Penning M, Lukashov V et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 244(2), 504-512 (1998).
    • (1998) Virology , vol.244 , Issue.2 , pp. 504-512
    • Beld, M.1    Penning, M.2    Lukashov, V.3
  • 13
    • 0035870682 scopus 로고    scopus 로고
    • Relation between HIV-1 and hepatitis C viral load in patients with hemophilia
    • Daar ES, Lynn H, Donfield S et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J. Acquir. Immune Defic. Syndr. 26(5), 466-472 (2001).
    • (2001) J. Acquir. Immune Defic. Syndr. , vol.26 , Issue.5 , pp. 466-472
    • Daar, E.S.1    Lynn, H.2    Donfield, S.3
  • 14
    • 0029878608 scopus 로고    scopus 로고
    • Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C
    • McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 23(4), 676-687 (1996).
    • (1996) Hepatology , vol.23 , Issue.4 , pp. 676-687
    • McGuinness, P.H.1    Bishop, G.A.2    Painter, D.M.3    Chan, R.4    McCaughan, G.W.5
  • 15
    • 0033954778 scopus 로고    scopus 로고
    • Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: A case-control study
    • The MULTIVIRC group
    • Allory Y, Charlotte F, Benhamou Y, Opolon P, Le Charpentier Y, Poynard T. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group. Hum. Pathol. 31(1), 69-74 (2000).
    • (2000) Hum. Pathol. , vol.31 , Issue.1 , pp. 69-74
    • Allory, Y.1    Charlotte, F.2    Benhamou, Y.3    Opolon, P.4    Le Charpentier, Y.5    Poynard, T.6
  • 16
    • 0032837102 scopus 로고    scopus 로고
    • Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
    • The Multivirc Group
    • Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30(4), 1054-1058 (1999).
    • (1999) Hepatology , vol.30 , Issue.4 , pp. 1054-1058
    • Benhamou, Y.1    Bochet, M.2    Di Martino, V.3
  • 17
    • 0034917518 scopus 로고    scopus 로고
    • Factors affecting liver fibrosis in human-immunodeficiency-virus- and hepatitis-C-virus-coinfected patients: Impact of protease inhibitor therapy
    • Benhamou Y, Di Martino V, Bochet M et al. Factors affecting liver fibrosis in human-immunodeficiency-virus- and hepatitis-C-virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34(2), 283-287 (2001).
    • (2001) Hepatology , vol.34 , Issue.2 , pp. 283-287
    • Benhamou, Y.1    Di Martino, V.2    Bochet, M.3
  • 18
    • 0037211571 scopus 로고    scopus 로고
    • HIV and HCV coinfection: Situation at six French university hospitals in the year 2000
    • Buffet-Janvresse C, Peigue-Lafeuille H, Benichou J et al. HIV and HCV coinfection: situation at six French university hospitals in the year 2000. J. Med. Virol. 69(l), 7-17 (2003).
    • (2003) J. Med. Virol. , vol.69 , Issue.1 , pp. 7-17
    • Buffet-Janvresse, C.1    Peigue-Lafeuille, H.2    Benichou, J.3
  • 19
    • 0342601406 scopus 로고    scopus 로고
    • Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
    • Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 26(1), 1-5 (1997).
    • (1997) J. Hepatol. , vol.26 , Issue.1 , pp. 1-5
    • Soto, B.1    Sanchez-Quijano, A.2    Rodrigo, L.3
  • 20
    • 0035112776 scopus 로고    scopus 로고
    • Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection
    • Bica I, McGovern B, Dhar R et al. Increasing mortality due to end stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32(3), 492-497 (2001).
    • (2001) Clin. Infect. Dis. , vol.32 , Issue.3 , pp. 492-497
    • Bica, I.1    McGovern, B.2    Dhar, R.3
  • 21
    • 0042232018 scopus 로고    scopus 로고
    • Mortality due to hepatitis-C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)
    • Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis-C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17(12), 1803-1809 (2003).
    • (2003) AIDS , vol.17 , Issue.12 , pp. 1803-1809
    • Rosenthal, E.1    Poiree, M.2    Pradier, C.3
  • 22
    • 0032953751 scopus 로고    scopus 로고
    • Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men
    • Colin JF; Cazals-Hatem D, Loriot MA et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29(4), 1306-1310 (1999).
    • (1999) Hepatology , vol.29 , Issue.4 , pp. 1306-1310
    • Colin, J.F.1    Cazals-Hatem, D.2    Loriot, M.A.3
  • 23
    • 0025779460 scopus 로고
    • The influence of human immunodeficiency virus Type 1 infection on the development of the hepatitis B virus carrier state
    • Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus Type 1 infection on the development of the hepatitis B virus carrier state. J. Infect. Dis. 163(5), 1138-1140 (1991).
    • (1991) J. Infect. Dis. , vol.163 , Issue.5 , pp. 1138-1140
    • Bodsworth, N.J.1    Cooper, D.A.2    Donovan, B.3
  • 24
    • 0032969855 scopus 로고    scopus 로고
    • Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection
    • Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J. Infect. Dis. 179(5), 1254-1258 (1999).
    • (1999) J. Infect. Dis. , vol.179 , Issue.5 , pp. 1254-1258
    • Lesens, O.1    Deschenes, M.2    Steben, M.3    Belanger, G.4    Tsoukas, C.M.5
  • 25
    • 0035882187 scopus 로고    scopus 로고
    • Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis
    • Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33(4), 562-569 (2001).
    • (2001) Clin. Infect. Dis. , vol.33 , Issue.4 , pp. 562-569
    • Graham, C.S.1    Baden, L.R.2    Yu, E.3
  • 26
    • 0034715950 scopus 로고    scopus 로고
    • Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
    • Greub G, Ledergerber B, Battegay M et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 356(9244), 1800-1805 (2000).
    • (2000) Lancet , vol.356 , Issue.9244 , pp. 1800-1805
    • Greub, G.1    Ledergerber, B.2    Battegay, M.3
  • 27
    • 0038163753 scopus 로고    scopus 로고
    • The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy
    • Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 33(3), 365-372 (2003).
    • (2003) J. Acquir. Immune Defic. Syndr. , vol.33 , Issue.3 , pp. 365-372
    • Klein, M.B.1    Lalonde, R.G.2    Suissa, S.3
  • 28
    • 0037024755 scopus 로고    scopus 로고
    • Is hepatitis C virus coinfection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?
    • Rancinan C, Neau D, Saves M et al.. Is hepatitis C virus coinfection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 16(10), 1357-1362 (2002).
    • (2002) AIDS , vol.16 , Issue.10 , pp. 1357-1362
    • Rancinan, C.1    Neau, D.2    Saves, M.3
  • 30
    • 12144270325 scopus 로고    scopus 로고
    • Hepatitis C (HCV) coinfection is preventing the realization of substantial health benefits associated with HAART
    • 11th Annual Canadian Conference on HIV/AIDS Research Winnipeg, Canada 25-28 April (Abstract 216)
    • Klein MB, LaLonde RG, Suissa S. Hepatitis C (HCV) coinfection is preventing the realization of substantial health benefits associated with HAART. 11th Annual Canadian Conference on HIV/AIDS Research. Winnipeg, Canada, 25-28 April 2002 (Abstract 216).
    • (2002)
    • Klein, M.B.1    LaLonde, R.G.2    Suissa, S.3
  • 31
    • 0033758378 scopus 로고    scopus 로고
    • Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients
    • Valdez H, Anthony D, Farukhi F et al. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 14(15), 2239-2246 (2000).
    • (2000) AIDS , vol.14 , Issue.15 , pp. 2239-2246
    • Valdez, H.1    Anthony, D.2    Farukhi, F.3
  • 32
    • 0033970794 scopus 로고    scopus 로고
    • Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C
    • Wiedmann M, Liebert UG, Oesen U et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 31(l), 230-234 (2000).
    • (2000) Hepatology , vol.31 , Issue.1 , pp. 230-234
    • Wiedmann, M.1    Liebert, U.G.2    Oesen, U.3
  • 33
    • 0031915859 scopus 로고    scopus 로고
    • Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
    • Keeffe EB, Iwarson S, McMahon BJ et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 27(3), 881-886 (1998).
    • (1998) Hepatology , vol.27 , Issue.3 , pp. 881-886
    • Keeffe, E.B.1    Iwarson, S.2    McMahon, B.J.3
  • 34
    • 0032582538 scopus 로고    scopus 로고
    • Binding of hepatitis C virus to CD81
    • Pileri P, Uematsu Y, Campagnoli S et al. Binding of hepatitis C virus to CD81. Science 282(5390), 938-941 (1998).
    • (1998) Science , vol.282 , Issue.5390 , pp. 938-941
    • Pileri, P.1    Uematsu, Y.2    Campagnoli, S.3
  • 35
    • 0028384692 scopus 로고
    • Presence of hepatitis C virus (HCV) genomic RNA and viral replicative intermediates in bone marrow and peripheral blood mononuclear cells from HCV-infected patients
    • Manzin A, Candela M, Paolucci S, Caniglia ML, Gabrielli A, Clementi M. Presence of hepatitis C virus (HCV) genomic RNA and viral replicative intermediates in bone marrow and peripheral blood mononuclear cells from HCV-infected patients. Clin. Diagn. Lab. Immunol. 1(2), 160-163 (1994).
    • (1994) Clin. Diagn. Lab. Immunol. , vol.1 , Issue.2 , pp. 160-163
    • Manzin, A.1    Candela, M.2    Paolucci, S.3    Caniglia, M.L.4    Gabrielli, A.5    Clementi, M.6
  • 36
    • 0032211159 scopus 로고    scopus 로고
    • Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers
    • Sansonno D, Lotesoriere C, Cornacchiulo V et al. Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 92(9), 3328-3337 (1998).
    • (1998) Blood , vol.92 , Issue.9 , pp. 3328-3337
    • Sansonno, D.1    Lotesoriere, C.2    Cornacchiulo, V.3
  • 37
    • 0034089003 scopus 로고    scopus 로고
    • Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus Type 1: Evidence of active replication in monocytes/macrophages and lymphocytes
    • Laskus T, Radkowski M, Piasek A et al. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus Type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J. Infect. Dis. 181(2), 442-448 (2000).
    • (2000) J. Infect. Dis. , vol.181 , Issue.2 , pp. 442-448
    • Laskus, T.1    Radkowski, M.2    Piasek, A.3
  • 39
    • 0034606721 scopus 로고    scopus 로고
    • Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
    • Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. J. Am. Med. Assoc. 283(1), 74-80 (2000).
    • (2000) J. Am. Med. Assoc. , vol.283 , Issue.1 , pp. 74-80
    • Sulkowski, M.S.1    Thomas, D.L.2    Chaisson, R.E.3    Moore, R.D.4
  • 40
    • 0035822989 scopus 로고    scopus 로고
    • Impact of protease inhibitors on intrahepatic hepatitis C virus vital load
    • Neau D, Trimoulet P, Winnock M et al. Impact of protease inhibitors on intrahepatic hepatitis C virus vital load. AIDS 15(13), 1736-1738 (2001).
    • (2001) AIDS , vol.15 , Issue.13 , pp. 1736-1738
    • Neau, D.1    Trimoulet, P.2    Winnock, M.3
  • 41
    • 18344367825 scopus 로고    scopus 로고
    • Intrahepatic HCV RNA loads in 37 HIV-HCV coinfected patients with controlled HIV infection
    • Trimoulet P, Neau D, Le Bail B et al. Intrahepatic HCV RNA loads in 37 HIV-HCV coinfected patients with controlled HIV infection. J. Med. Virol. 67(2), 143-151 (2002).
    • (2002) J. Med. Virol. , vol.67 , Issue.2 , pp. 143-151
    • Trimoulet, P.1    Neau, D.2    Le Bail, B.3
  • 42
    • 0037183911 scopus 로고    scopus 로고
    • Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects
    • Chung RT, Evans SR, Yang Y et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in coinfected subjects. AIDS 16(14), 1915-1923 (2002).
    • (2002) AIDS , vol.16 , Issue.14 , pp. 1915-1923
    • Chung, R.T.1    Evans, S.R.2    Yang, Y.3
  • 43
    • 0035503612 scopus 로고    scopus 로고
    • Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy
    • Torre D, Tambini R, Cadario F, Barbarini G, Moroni M, Basilico C. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin. Infect. Dis. 33(9), 1579-1585 (2001).
    • (2001) Clin. Infect. Dis. , vol.33 , Issue.9 , pp. 1579-1585
    • Torre, D.1    Tambini, R.2    Cadario, F.3    Barbarini, G.4    Moroni, M.5    Basilico, C.6
  • 44
    • 0142030002 scopus 로고    scopus 로고
    • Alanine aminotransferase decrease in HIV-hepatitis C virus coinfected patients responding to antiretroviral therapy
    • Aceti A, Pasquazzi C, Zechini B. Alanine aminotransferase decrease in HIV-hepatitis C virus coinfected patients responding to antiretroviral therapy. AIDS 17(14), 2141-2142 (2003).
    • (2003) AIDS , vol.17 , Issue.14 , pp. 2141-2142
    • Aceti, A.1    Pasquazzi, C.2    Zechini, B.3
  • 46
    • 0032480896 scopus 로고    scopus 로고
    • Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
    • John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 12(17), 2289-2293 (1998).
    • (1998) AIDS , vol.12 , Issue.17 , pp. 2289-2293
    • John, M.1    Flexman, J.2    French, M.A.3
  • 47
    • 0344120830 scopus 로고    scopus 로고
    • Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection
    • Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362(9397), 1708-1713 (2003).
    • (2003) Lancet , vol.362 , Issue.9397 , pp. 1708-1713
    • Qurishi, N.1    Kreuzberg, C.2    Luchters, G.3
  • 48
    • 11144358566 scopus 로고    scopus 로고
    • Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine
    • Macias J, Castellano V, Merchante N et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18(5), 767-774 (2004).
    • (2004) AIDS , vol.18 , Issue.5 , pp. 767-774
    • Macias, J.1    Castellano, V.2    Merchante, N.3
  • 49
    • 0141644715 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate and lamivudine combination therapy compared to lamivudine alone for HBV in therapynaive HIV/HBV coinfected patients: 48-week interim results
    • Boston MA USA, 10-14 February (Abstract 825)
    • Cooper D, Gore D, Pozniak AL et al. Tenofovir disoproxil fumarate and lamivudine combination therapy compared to lamivudine alone for HBV in therapynaive HIV/HBV coinfected patients: 48-week interim results. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 10-14 February 2003 (Abstract 825).
    • (2003) 10th Conference on Retroviruses and Opportunistic Infections
    • Cooper, D.1    Gore, D.2    Pozniak, A.L.3
  • 50
    • 0034457420 scopus 로고    scopus 로고
    • Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine
    • Prometheus Study Group
    • Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin. Infect. Dis. 31(5), 1234-1239 (2000).
    • (2000) Clin. Infect. Dis. , vol.31 , Issue.5 , pp. 1234-1239
    • Gisolf, E.H.1    Dreezen, C.2    Danner, S.A.3    Weel, J.L.4    Weverling, G.J.5
  • 51
    • 0035956691 scopus 로고    scopus 로고
    • Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
    • Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357(9252), 280-281 (2001).
    • (2001) Lancet , vol.357 , Issue.9252 , pp. 280-281
    • Lafeuillade, A.1    Hittinger, G.2    Chadapaud, S.3
  • 53
    • 0029154249 scopus 로고
    • Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
    • Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am. J. Gastroenterol. 90(9), 1433-1436 (1995).
    • (1995) Am. J. Gastroenterol. , vol.90 , Issue.9 , pp. 1433-1436
    • Fortgang, I.S.1    Belitsos, P.C.2    Chaisson, R.E.3    Moore, R.D.4
  • 54
    • 0033985675 scopus 로고    scopus 로고
    • Lactic acidosis associated with stavudine administration: A report of five cases
    • Mokrzycki MH, Harris C, May H, Laut J, Palmisano J. Lactic acidosis associated with stavudine administration: a report of five cases. Clin. Infect. Dis. 30(1), 198-200 (2000).
    • (2000) Clin. Infect. Dis. , vol.30 , Issue.1 , pp. 198-200
    • Mokrzycki, M.H.1    Harris, C.2    May, H.3    Laut, J.4    Palmisano, J.5
  • 55
    • 0028966460 scopus 로고
    • Five-year follow-up of a Phase I study of didanosine in patients with advanced human immunodeficiency virus infection
    • Nguyen BY, Yarchoan R, Wyvill KM et al. Five-year follow-up of a Phase I study of didanosine in patients with advanced human immunodeficiency virus infection. J. Infect. Dis. 171(5), 1180-1189 (1995).
    • (1995) J. Infect. Dis. , vol.171 , Issue.5 , pp. 1180-1189
    • Nguyen, B.Y.1    Yarchoan, R.2    Wyvill, K.M.3
  • 56
    • 0032189850 scopus 로고    scopus 로고
    • Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
    • Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12(14), 1735-1744 (1998).
    • (1998) AIDS , vol.12 , Issue.14 , pp. 1735-1744
    • Brinkman, K.1    ter Hofstede, H.J.2    Burger, D.M.3    Smeitink, J.A.4    Koopmans, P.P.5
  • 57
    • 0036153954 scopus 로고    scopus 로고
    • Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: The role of hepatitis B and C virus infection
    • Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J. Acquir. Immune Defic. Syndr. 29(l), 41-48 (2002).
    • (2002) J. Acquir. Immune Defic. Syndr. , vol.29 , Issue.1 , pp. 41-48
    • Aceti, A.1    Pasquazzi, C.2    Zechini, B.3    De Bac, C.4
  • 58
    • 0036139688 scopus 로고    scopus 로고
    • Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
    • Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35(l), 182-189 (2002).
    • (2002) Hepatology , vol.35 , Issue.1 , pp. 182-189
    • Sulkowski, M.S.1    Thomas, D.L.2    Mehta, S.H.3    Chaisson, R.E.4    Moore, R.D.5
  • 59
    • 4644262439 scopus 로고    scopus 로고
    • Treatment of HIV+ subjects coinfected with hepatitis B or C: Week 60 safety and efficacy comparison of lopinavir/ritonavir vs. nelfinavir from a Phase III blinded randomized clinical trial
    • Athens, Greece, 28-31 October (Abstract P228)
    • Bernstein B, King M, Cernohous P, Moseley J, Sun E. Treatment of HIV+ subjects coinfected with hepatitis B or C: week 60 safety and efficacy comparison of lopinavir/ritonavir vs. nelfinavir from a Phase III blinded randomized clinical trial. 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, Greece, 28-31 October 2001 (Abstract P228).
    • (2001) 8th European Conference on Clinical Aspects and Treatment of HIV Infection
    • Bernstein, B.1    King, M.2    Cernohous, P.3    Moseley, J.4    Sun, E.5
  • 60
    • 0037182766 scopus 로고    scopus 로고
    • Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
    • Walmsley S, Bernstein B, King M et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346(26), 2039-2046 (2002).
    • (2002) N. Engl. J. Med. , vol.346 , Issue.26 , pp. 2039-2046
    • Walmsley, S.1    Bernstein, B.2    King, M.3
  • 61
    • 0036642493 scopus 로고    scopus 로고
    • Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy
    • Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis. 186(l), 23-31 (2002).
    • (2002) J. Infect. Dis. , vol.186 , Issue.1 , pp. 23-31
    • Wit, F.W.1    Weverling, G.J.2    Weel, J.3    Jurriaans, S.4    Lange, J.M.5
  • 62
    • 0036569989 scopus 로고    scopus 로고
    • Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus
    • Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin. Infect. Dis. 34(9), 1259-1263 (2002).
    • (2002) Clin. Infect. Dis. , vol.34 , Issue.9 , pp. 1259-1263
    • Cooper, C.L.1    Parbhakar, M.A.2    Angel, J.B.3
  • 63
    • 11144357656 scopus 로고    scopus 로고
    • Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A randomized open-label trial, the 2NN Study
    • van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 363(9417), 1253-1263 (2004).
    • (2004) Lancet , vol.363 , Issue.9417 , pp. 1253-1263
    • van Leth, F.1    Phanuphak, P.2    Ruxrungtham, K.3
  • 64
    • 0035816360 scopus 로고    scopus 로고
    • Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
    • Martinez E, Blanco JL, Arnaiz JA et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15(10), 1261-1268 (2001).
    • (2001) AIDS , vol.15 , Issue.10 , pp. 1261-1268
    • Martinez, E.1    Blanco, J.L.2    Arnaiz, J.A.3
  • 65
    • 0032450165 scopus 로고    scopus 로고
    • DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome associated with nevirapine therapy
    • Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R. DRESS (Drug Rash with Eosinophilia and Systemic Symptoms) syndrome associated with nevirapine therapy. Clin. Infect. Dis. 27(5), 1321-1322 (1998).
    • (1998) Clin. Infect. Dis. , vol.27 , Issue.5 , pp. 1321-1322
    • Bourezane, Y.1    Salard, D.2    Hoen, B.3    Vandel, S.4    Drobacheff, C.5    Laurent, R.6
  • 66
    • 0037471311 scopus 로고    scopus 로고
    • A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    • Lalezari JP, Eron JJ, Carlson M et al. A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17(5), 691-698 (2003).
    • (2003) AIDS , vol.17 , Issue.5 , pp. 691-698
    • Lalezari, J.P.1    Eron, J.J.2    Carlson, M.3
  • 67
    • 0038576281 scopus 로고    scopus 로고
    • Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    • Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348(22), 2175-2185 (2003).
    • (2003) N. Engl. J. Med. , vol.348 , Issue.22 , pp. 2175-2185
    • Lalezari, J.P.1    Henry, K.2    O'Hearn, M.3
  • 68
    • 0033756205 scopus 로고    scopus 로고
    • Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
    • Zylberberg H, Benhamou Y, Lagneaux JL et al. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 47(5), 694-697 (2000).
    • (2000) Gut , vol.47 , Issue.5 , pp. 694-697
    • Zylberberg, H.1    Benhamou, Y.2    Lagneaux, J.L.3
  • 69
    • 0038548200 scopus 로고    scopus 로고
    • Comparison of 2 regimens that include interferon-α-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients
    • Neau D, Trimoulet P, Winnock M et al. Comparison of 2 regimens that include interferon-α-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin. Infect. Dis. 36(12), 1564-1571 (2003).
    • (2003) Clin. Infect. Dis. , vol.36 , Issue.12 , pp. 1564-1571
    • Neau, D.1    Trimoulet, P.2    Winnock, M.3
  • 70
    • 0035834534 scopus 로고    scopus 로고
    • Long-term efficacy of combination therapy with interferon-α 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
    • Landau A, Batisse D, Piketty C et al. Long-term efficacy of combination therapy with interferon-α 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 15(16), 2149-2155 (2001).
    • (2001) AIDS , vol.15 , Issue.16 , pp. 2149-2155
    • Landau, A.1    Batisse, D.2    Piketty, C.3
  • 71
    • 3343012408 scopus 로고    scopus 로고
    • Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
    • Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351(5), 438-450 (2004).
    • (2004) N. Engl. J. Med. , vol.351 , Issue.5 , pp. 438-450
    • Torriani, F.J.1    Rodriguez-Torres, M.2    Rockstroh, J.K.3
  • 72
    • 4444270265 scopus 로고    scopus 로고
    • Peginterferon α-2b plus ribavirin compared with interferon α2b plus ribavirin for treatment of HIV/HCV coinfected patients
    • Laguno M, Murillas J, Blanco JL et al. Peginterferon α-2b plus ribavirin compared with interferon α2b plus ribavirin for treatment of HIV/HCV coinfected patients. AIDS 18(13), F27-F36 (2004).
    • (2004) AIDS , vol.18 , Issue.13
    • Laguno, M.1    Murillas, J.2    Blanco, J.L.3
  • 73
    • 3342892905 scopus 로고    scopus 로고
    • Peginterferon α-2a plus ribavirin versus interferon α2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    • Chung RT, Andersen J, Volberding P et al. Peginterferon α-2a plus ribavirin versus interferon α2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N. Engl. J. Med. 351(5), 451-459 (2004).
    • (2004) N. Engl. J. Med. , vol.351 , Issue.5 , pp. 451-459
    • Chung, R.T.1    Andersen, J.2    Volberding, P.3
  • 74
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial
    • Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358(9286), 958-965 (2001).
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 75
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
    • (2002) N. Engl. J. Med. , vol.347 , Issue.13 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 76
    • 14044261536 scopus 로고    scopus 로고
    • Poor tolerability to high-dose peginterferon and ribavirin in HIV/HCV coinfected patients; initial results from a randomized multicenter trial
    • 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 24-28 October (Abstract 347)
    • Hammoud G, Li J, Vega K et al. Poor tolerability to high-dose peginterferon and ribavirin in HIV/HCV coinfected patients; initial results from a randomized multicenter trial. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 24-28 October 2003 (Abstract 347).
    • (2003)
    • Hammoud, G.1    Li, J.2    Vega, K.3
  • 78
    • 0035958765 scopus 로고    scopus 로고
    • Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN-α results from the Primoferon A (ANRS 086) Study
    • Emilie D, Burgard M, Lascoux-Combe C et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN-α results from the Primoferon A (ANRS 086) Study. AIDS 15(11), 1435-1437 (2001).
    • (2001) AIDS , vol.15 , Issue.11 , pp. 1435-1437
    • Emilie, D.1    Burgard, M.2    Lascoux-Combe, C.3
  • 79
    • 0033592764 scopus 로고    scopus 로고
    • Lamivudine as intial treatment for chronic hepatitis B in the United States
    • Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as intial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341(17), 1256-1263 (1999).
    • (1999) N. Engl. J. Med. , vol.341 , Issue.17 , pp. 1256-1263
    • Dienstag, J.L.1    Schiff, E.R.2    Wright, T.L.3
  • 80
    • 0034105307 scopus 로고    scopus 로고
    • Lamivudine and α-interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial
    • Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and α-interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 46(4), 562-568 (2000).
    • (2000) Gut , vol.46 , Issue.4 , pp. 562-568
    • Schalm, S.W.1    Heathcote, J.2    Cianciara, J.3
  • 81
    • 0034879623 scopus 로고    scopus 로고
    • Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B
    • Da Silva LC, Pinho JR, Sitnik R, Da Fonseca LE, Carrilho FJ. Effcacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J. Gastroenterol. 36(7), 476-485 (2001).
    • (2001) J. Gastroenterol. , vol.36 , Issue.7 , pp. 476-485
    • Da Silva, L.C.1    Pinho, J.R.2    Sitnik, R.3    Da Fonseca, L.E.4    Carrilho, F.J.5
  • 82
    • 0032760120 scopus 로고    scopus 로고
    • Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
    • Behamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30(5), 1302-1306 (1999).
    • (1999) Hepatology , vol.30 , Issue.5 , pp. 1302-1306
    • Behamou, Y.1    Bochet, M.2    Thibault, V.3
  • 83
    • 14044258097 scopus 로고    scopus 로고
    • Antihepatitis B virus (HBV) activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV coinfected patients
    • XIV International AIDS Conference. Barcelona, Spain, 7-12 July (Abstract 6015)
    • Cooper D, Coakley DF, Sayre J et al. Antihepatitis B virus (HBV) activity of tenofovir disoproxil fumarate (TDF) in lamivudine (LAM) experienced HIV/HBV coinfected patients. XIV International AIDS Conference. Barcelona, Spain, 7-12 July 2002 (Abstract 6015).
    • (2002)
    • Cooper, D.1    Coakley, D.F.2    Sayre, J.3
  • 84
    • 0011588006 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patiens coinfected with HIV/HBV
    • Seattle WA USA, 24-28 February (Abstract 675-M)
    • Bochet M, Tubiana R, Benhamou Y et al. Tenofovir disoproxil fumarate suppresses lamivudine-resistant HBV replication in patiens coinfected with HIV/HBV. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 24-28 February 2003 (Abstract 675-M).
    • (2003) 9th Conference on Retroviruses and Opportunistic Infections
    • Bochet, M.1    Tubiana, R.2    Benhamou, Y.3
  • 85
    • 0035915622 scopus 로고    scopus 로고
    • Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
    • Nishiguchi S, Shiomi S, Nakatani S et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357(9251), 196-197 (2001).
    • (2001) Lancet , vol.357 , Issue.9251 , pp. 196-197
    • Nishiguchi, S.1    Shiomi, S.2    Nakatani, S.3
  • 86
    • 0037452519 scopus 로고    scopus 로고
    • Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus
    • Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 138(4), 299-306 (2003).
    • (2003) Ann. Intern. Med. , vol.138 , Issue.4 , pp. 299-306
    • Shiratori, Y.1    Shiina, S.2    Teratani, T.3
  • 87
    • 14044253102 scopus 로고    scopus 로고
    • Serum α-fetoprotein (AFP) levels in patients with advanced hepatitis-C-associated liver disease without hepatocellular carcinoma: Results from the HALT-C trial
    • 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MN, USA, 24-28 October (Abstract 567)
    • Di Bisceglie AM, Dienstag J, Bankovsky H et al. Serum α-fetoprotein (AFP) levels in patients with advanced hepatitis-C-associated liver disease without hepatocellular carcinoma: results from the HALT-C trial. 54th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MN, USA, 24-28 October 2003 (Abstract 567).
    • (2003)
    • Di Bisceglie, A.M.1    Dienstag, J.2    Bankovsky, H.3
  • 88
    • 0037372134 scopus 로고    scopus 로고
    • Hepatitis C and alcohol: Interactions, outcomes and implications
    • Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes and implications. J. Clin. Gastroenterol. 36(3), 242-252 (2003).
    • (2003) J. Clin. Gastroenterol. , vol.36 , Issue.3 , pp. 242-252
    • Bhattacharya, R.1    Shuhart, M.C.2
  • 89
    • 0036904004 scopus 로고    scopus 로고
    • Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy
    • Tabone M, Sidoli L, Laudi C et al. Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy. J. Viral Hepat. 9(4), 288-294 (2002).
    • (2002) J. Viral Hepat. , vol.9 , Issue.4 , pp. 288-294
    • Tabone, M.1    Sidoli, L.2    Laudi, C.3
  • 91
    • 0036829486 scopus 로고    scopus 로고
    • Prevention and treatment of hepatitis C in injection drug users
    • Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 36(5 Suppl. 1), S210-S219 (2002).
    • (2002) Hepatology , vol.36 , Issue.5 SUPPL. 1
    • Edlin, B.R.1
  • 92
    • 0141673558 scopus 로고    scopus 로고
    • First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C geneotype 1
    • 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October (Abstract 567)
    • Hinrichsen H, Benhamou Y, Reiser M et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C geneotype 1. 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October 2004 (Abstract 567).
    • (2004)
    • Hinrichsen, H.1    Benhamou, Y.2    Reiser, M.3
  • 93
    • 14044264456 scopus 로고    scopus 로고
    • Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor,after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis
    • 55th Annual Meeting of the American Association for the Study of Liver Diseaes. Boston, MA, USA, 29 October (Abstract 563)
    • Benhamou Y, Hinrichsen H, Sentjens R et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor,after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. 55th Annual Meeting of the American Association for the Study of Liver Diseaes Boston, MA, USA, 29 October 2004 (Abstract 563).
    • (2004)
    • Benhamou, Y.1    Hinrichsen, H.2    Sentjens, R.3
  • 94
    • 14044274521 scopus 로고    scopus 로고
    • Discovery and preclinical characterization of novel inhibitors of the HCV NS3/4 protease
    • 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October (Abstract LB14)
    • Seiwert S, Tan H, Rieger R et al. Discovery and preclinical characterization of novel inhibitors of the HCV NS3/4 protease. 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October 2004 (Abstract LB14).
    • (2004)
    • Seiwert, S.1    Tan, H.2    Rieger, R.3
  • 95
    • 33645407406 scopus 로고    scopus 로고
    • Final Phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: Antivirial efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures
    • 55th Annual Meeting of the AMerican Association for the Study of Liver Diseases. Boston, MA, USA, 29 October (Abstract LB03)
    • Afdhal N, Godofsky E, Dienstag J et al. Final Phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antivirial efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. 55th Annual Meeting of the AMerican Association for the Study of Liver Diseases. Boston, MA, USA, 29 October 2004 (Abstract LB03).
    • (2004)
    • Afdhal, N.1    Godofsky, E.2    Dienstag, J.3
  • 96
    • 14044264457 scopus 로고    scopus 로고
    • Results of a Phase 1 single-dose escalation study ofthe hepatitis C protease inhibitor VX-950 in healthy volunteers
    • 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October (Abstract LB20)
    • Chu HM, McNair L, Purdy S. Results of a Phase 1 single-dose escalation study ofthe hepatitis C protease inhibitor VX-950 in healthy volunteers. 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October 2004 (Abstract LB20).
    • (2004)
    • Chu, H.M.1    McNair, L.2    Purdy, S.3
  • 97
    • 14044255068 scopus 로고    scopus 로고
    • Entecavir demonstrate superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBEAG (-) chronic hepatitis B: Results of Phase III trial ETV-027
    • 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October (Abstract LB07)
    • Shouval D, Lai CL, Cheinquer H et al. Entecavir demonstrate superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBEAG (-) chronic hepatitis B: results of Phase III trial ETV-027. 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October 2004 (Abstract LB07).
    • (2004)
    • Shouval, D.1    Lai, C.L.2    Cheinquer, H.3
  • 98
    • 11344257404 scopus 로고    scopus 로고
    • CPG7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind Phase I/II study
    • Cooper CL, Davis HL, Morris ML et al. CPG7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol. 24(6), 693-701 (2004).
    • (2004) J. Clin. Immunol. , vol.24 , Issue.6 , pp. 693-701
    • Cooper, C.L.1    Davis, H.L.2    Morris, M.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.